USD 72.44
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ADC | 0.4 | 5.8 | -1.2 | -4.5 | 7.6 | 18.0 | 8.0 | -0.1 | 116.0 | 271.5 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ADC |
| name | Agree Realty Corporation |
| price | 72.44 |
| changes percentage | 0.40 |
| change | 0.29 |
| day low | 71.88 |
| day high | 72.88 |
| year high | 78.39 |
| year low | 54.28 |
| market cap | 7499206120 |
| price avg 50 | 73.44 |
| price avg 200 | 68.31 |
| exchange | NYSE |
| volume | 605507 |
| avg volume | 996473 |
| open | 72.29 |
| previous close | 72.15 |
| eps | 1.85 |
| pe | 39.16 |
| earnings announcement | 2025-02-11T21:00:00.000+0000 |
| shares outstanding | 103523000 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000917251 | |||
| revenue | 537495000 | 463151000 | 16.05 |
| gross profit | 470778000 | 377533000 | 24.70 |
| gross profit ratio | 0.88 | 0.82 | 7.45 |
| research and development expenses | 0 | 0.37 | -100.00 |
| operating expenses | 216391000 | 163691000 | 32.19 |
| interest income | 0 | 63435000 | -100.00 |
| interest expense | 81119000 | 63435000 | 27.88 |
| ebitda | 463949000 | 386237000 | 20.12 |
| ebitdaratio | 0.86 | 0.74 | 16.52 |
| operating income | 254387000 | 218085000 | 16.65 |
| operating income ratio | 0.47 | 0.47 | 0.51 |
| net income | 169959000 | 152437000 | 11.49 |
| net income ratio | 0.32 | 0.33 | -3.93 |
| eps | 1.7 | 1.84 | -7.61 |
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000917251 | |||
| revenue | 154332000 | 152575000 | 1.15 |
| gross profit | 84457000 | 84498000 | -0.05 |
| gross profit ratio | 0.55 | 0.55 | -1.19 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 9114000 | 60161000 | -84.85 |
| interest income | 0 | 0 | NaN |
| interest expense | 28942000 | 26416000 | 9.56 |
| ebitda | 134345000 | 125660000 | 6.91 |
| ebitdaratio | 0.87 | 0.82 | 5.69 |
| operating income | 74443000 | 74791000 | -0.47 |
| operating income ratio | 0.48 | 0.49 | -1.60 |
| net income | 44375000 | 54724000 | -18.91 |
| net income ratio | 0.29 | 0.36 | -19.83 |
| eps | 0.42 | 0.53 | -20.75 |
Revenue Growth: revenue increased to 154 million in 2024Q3 from 153 million in 2024Q2 representing a change of 1.15%. This indicates a sales growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 134 million in 2024Q3 from 126 million in 2024Q2 representing a change of 6.91%. The increase in EBITDA indicates improved operational efficiency and profitability.
Gross Profit: Gross Profit decreased to 84 million in 2024Q3 from 84 million in 2024Q2 representing a change of -0.05%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 9 million in 2024Q3 from 60 million in 2024Q2 representing a change of -84.85%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to 74 million in 2024Q3 from 75 million in 2024Q2 representing a change of -0.47%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 44 million in 2024Q3 from 55 million in 2024Q2 representing a change of -18.91%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0.42 in 2024Q3 from 0.42 in 2024Q2 representing a change of -20.75%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000917251 | |||
| total assets | 7774836000 | 6713189000 | 15.81 |
| total liabilities | 2574683000 | 2082799000 | 23.62 |
| total equity | 5200153000 | 4630390000 | 12.30 |
| cash and cash equivalents | 10907000 | 27763000 | -60.71 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | -6713189000 | 100.00 |
| total current assets | 101120000 | 94750000 | 6.72 |
| total non current assets | 7673716000 | 6618439000 | 15.94 |
| total current liabilities | 89320000 | 106067000 | -15.79 |
| total non current liabilities | 2447748000 | 1976732000 | 23.83 |
| common stock | 10000 | 9000 | 11.11 |
| retained earnings | -346473000 | -228132000 | -51.87 |
| total debt | 2410921000 | 1940018000 | 24.27 |
Total Assets: Total Assets increased to 7,775 million in 2023 from 6,713 million in 2022 representing a change of 15.81%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 5,200 million in 2023 from 4,630 million in 2022 representing a change of 12.3%. This indicates an increase in shareholders' equity.
Total Current Assets: Total Current Assets increased to 101 million in 2023 from 95 million in 2022 representing a change of 6.72%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 89 million in 2023 from 106 million in 2022 representing a change of -15.79%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 11.11%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 2,575 million in 2023 from 2,083 million in 2022 representing a change of 23.62%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 11 million in 2023 from 28 million in 2022 representing a change of -60.71%. This indicates a decrease in available liquid assets.
Retained Earnings: Retained Earnings decreased to -346 million in 2023 from -228 million in 2022 representing a change of -51.87%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 2,411 million in 2023 from 1,940 million in 2022 representing a change of 24.27%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000917251 | |||
| total assets | 8184203000 | 8000838000 | 2.29 |
| total liabilities | 2889573000 | 2837760000 | 1.83 |
| total equity | 5294630000 | 5163078000 | 2.55 |
| cash and cash equivalents | 13237000 | 24254000 | -45.42 |
| short term investments | 0 | 6859999 | -100.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 125053000 | 119107000 | 4.99 |
| total non current assets | 837865000 | 7881731000 | -89.37 |
| total current liabilities | 168783000 | 131921000 | 27.94 |
| total non current liabilities | 2720790000 | 2705839000 | 0.55 |
| common stock | 10000 | 10000 | 0.00 |
| retained earnings | -434485000 | -400809000 | -8.40 |
| total debt | 2675588000 | 2728898000 | -1.95 |
Total Assets: Total Assets increased to 8,184 million in 2024Q3 from 8,001 million in 2024Q2 representing a change of 2.29%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 5,295 million in 2024Q3 from 5,163 million in 2024Q2 representing a change of 2.55%. This indicates an increase in shareholders' equity.
Total Current Assets: Total Current Assets increased to 125 million in 2024Q3 from 119 million in 2024Q2 representing a change of 4.99%. This indicates a better liquidity position.
Total Debt: Total Debt decreased to 2,676 million in 2024Q3 from 2,729 million in 2024Q2 representing a change of -1.95%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 2,890 million in 2024Q3 from 2,838 million in 2024Q2 representing a change of 1.83%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 13 million in 2024Q3 from 24 million in 2024Q2 representing a change of -45.42%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2024Q3 from 7 million in 2024Q2 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 169 million in 2024Q3 from 132 million in 2024Q2 representing a change of 27.94%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -434 million in 2024Q3 from -401 million in 2024Q2 representing a change of -8.4%. This indicates an accumulated losses.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000917251 | |||
| net change in cash | -14385000 | -16341000 | 11.97 |
| operating cash flow | 391598000 | 362121000 | 8.14 |
| free cash flow | 391598000 | 362121000 | 8.14 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 209373000 | 166907000 | 25.44 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 8338000 | 6464000 | 28.99 |
| accounts payables | 10384000 | 15048000 | -30.99 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | -1274997000 | -1615975000 | 21.10 |
| debt repayment | 471473000 | 213023000 | 121.32 |
| common stock issued | 689896000 | 1257823000 | -45.15 |
| common stock repurchased | -2684000 | -1912000 | -40.38 |
| dividends paid | -285113000 | -227742000 | -25.19 |
| net cash used provided by financing activities | 869014000 | 1237513000 | -29.78 |
| cash at end of period | 14524000 | 28909000 | -49.76 |
| accounts receivables | -5086000 | 799000 | -736.55 |
| cash at beginning of period | 28909000 | 45250000 | -36.11 |
Net Change in Cash: Net Change in Cash increased to -14 million in 2023 from -16 million in 2022 representing a change of 11.97%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 392 million in 2023 from 362 million in 2022 representing a change of 8.14%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 392 million in 2023 from 362 million in 2022 representing a change of 8.14%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 10 million in 2023 from 15 million in 2022 representing a change of -30.99%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -5 million in 2023 from 1 million in 2022 representing a change of -736.55%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Stock-Based Compensation: Stock-Based Compensation increased to 8 million in 2023 from 6 million in 2022 representing a change of 28.99%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Dividends Paid: Dividends Paid decreased to -285 million in 2023 from -228 million in 2022 representing a change of -25.19%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000917251 | |||
| operating cash flow | 140456000 | 92907000 | 51.18 |
| free cash flow | 140456000 | 92907000 | 51.18 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 59798000 | 50869000 | 17.55 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 2780000 | 2788000 | -0.29 |
| accounts receivables | -227000 | -676000 | 66.42 |
| accounts payables | 36779000 | -15641000 | 335.14 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | -246825000 | -164277000 | -50.25 |
| debt repayment | 5757000 | 157483000 | -96.34 |
| common stock issued | 175127000 | 0 | NaN |
| common stock repurchased | -72000 | -7000 | -928.57 |
| dividends paid | -77328000 | -77027000 | -0.39 |
| net cash used provided by financing activities | 95352000 | 80190000 | 18.91 |
| net change in cash | -11017000 | 8820000 | -224.91 |
| cash at end of period | 13237000 | 24254000 | -45.42 |
| cash at beginning of period | 24254000 | 15434000 | 57.15 |
Net Change in Cash: Net Change in Cash decreased to -11 million in 2024Q3 from 9 million in 2024Q2 representing a change of -224.91%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Accounts Payables: The absolute value of Accounts Payables increased to 37 million in 2024Q3 from 16 million in 2024Q2 representing a change of 335.14%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q3 from -1 million in 2024Q2 representing a change of 66.42%. This suggests that the company is less capable of collecting payments from its customers.
Dividends Paid: Dividends Paid decreased to -77 million in 2024Q3 from -77 million in 2024Q2 representing a change of -0.39%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
Operating Cash Flow: Operating Cash Flow increased to 140 million in 2024Q3 from 93 million in 2024Q2 representing a change of 51.18%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 140 million in 2024Q3 from 93 million in 2024Q2 representing a change of 51.18%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 3 million in 2024Q3 from 3 million in 2024Q2 representing a change of -0.29%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 5.65 | 5.89 | -4.10 |
| net income per share | 1.79 | 1.94 | -7.87 |
| operating cash flow per share | 4.11 | 4.6 | -10.64 |
| free cash flow per share | 4.11 | 4.6 | -10.64 |
| cash per share | 0.11 | 0.35 | -67.54 |
| book value per share | 54.63 | 58.87 | -7.20 |
| tangible book value per share | 45.66 | 48.7 | -6.26 |
| shareholders equity per share | 54.62 | 58.85 | -7.19 |
| interest debt per share | 26.18 | 25.47 | 2.78 |
| market cap | 5992299196.55 | 5579306489.69 | 7.40 |
| enterprise value | 8392313196.55 | 7491561489.69 | 12.02 |
| pe ratio | 35.26 | 36.6 | -3.67 |
| price to sales ratio | 11.15 | 12.05 | -7.45 |
| pocfratio | 15.3 | 15.41 | -0.68 |
| pfcf ratio | 15.3 | 15.41 | -0.68 |
| pb ratio | 1.15 | 1.21 | -4.38 |
| ptb ratio | 1.15 | 1.21 | -4.38 |
| ev to sales | 15.61 | 16.18 | -3.47 |
| enterprise value over ebitda | 18.09 | 19.4 | -6.74 |
| ev to operating cash flow | 21.43 | 20.69 | 3.59 |
| ev to free cash flow | 21.43 | 20.69 | 3.59 |
| earnings yield | 0.03 | 0.03 | 3.81 |
| free cash flow yield | 0.07 | 0.06 | 0.69 |
| debt to equity | 0.46 | 0.42 | 10.64 |
| debt to assets | 0.31 | 0.29 | 7.30 |
| net debt to ebitda | 5.17 | 4.95 | 4.48 |
| current ratio | 1.13 | 0.89 | 26.73 |
| interest coverage | 3.14 | 3.44 | -8.78 |
| income quality | 2.3 | 2.37 | -2.96 |
| dividend yield | 0.05 | 0.04 | 16.56 |
| payout ratio | 1.68 | 1.49 | 12.28 |
| sales general and administrative to revenue | 0.06 | 0.07 | -0.48 |
| research and ddevelopement to revenue | 0 | 0.0 | -100.00 |
| intangibles to total assets | 0.11 | 0.12 | -7.75 |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0.02 | 0.01 | 11.15 |
| graham number | 46.84 | 50.66 | -7.53 |
| roic | 0.03 | 0.03 | 0.51 |
| return on tangible assets | 0.02 | 0.03 | -4.73 |
| graham net net | -26.28 | -24.89 | -5.59 |
| working capital | 11800000 | -11317000 | 204.27 |
| tangible asset value | 4346065000 | 3830942000 | 13.45 |
| net current asset value | -2473563000 | -1988049000 | -24.42 |
| invested capital | 7669408000 | 6590099000 | 16.38 |
| average receivables | 74397499.5 | 59641499.5 | 24.74 |
| average payables | 67866500 | 76863500 | -11.71 |
| average inventory | 47948000 | 101131000 | -52.59 |
| days sales outstanding | 56.33 | 51.89 | 8.56 |
| days payables outstanding | 284.55 | 356.92 | -20.28 |
| days of inventory on hand | 0 | 408.82 | -100.00 |
| receivables turnover | 6.48 | 7.03 | -7.89 |
| payables turnover | 1.28 | 1.02 | 25.43 |
| inventory turnover | 0 | 0.89 | -100.00 |
| roe | 0.03 | 0.03 | -0.73 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to 0.03 on 2023-12-31 from 0.03 on 2022-12-31, representing a change of -0.73%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 35.26 on 2023-12-31 from 36.60 on 2022-12-31, representing a change of -3.67%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 1.13 on 2023-12-31 from 0.89 on 2022-12-31, representing a change of 26.73%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.46 on 2023-12-31 from 0.42 on 2022-12-31, representing a change of 10.64%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ADC | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 1.54 | 1.52 | 1.12 |
| net income per share | 0.44 | 0.55 | -18.94 |
| operating cash flow per share | 1.4 | 0.93 | 51.13 |
| free cash flow per share | 1.4 | 0.93 | 51.13 |
| cash per share | 0.13 | 0.31 | -57.47 |
| book value per share | 52.74 | 51.45 | 2.51 |
| tangible book value per share | 44.4 | 43.1 | 3.01 |
| shareholders equity per share | 52.74 | 51.44 | 2.52 |
| interest debt per share | 26.94 | 27.46 | -1.88 |
| market cap | 7561866983.31 | 6188580984.81 | 22.19 |
| enterprise value | 10224217983.31 | 8893224984.81 | 14.97 |
| pe ratio | 42.6 | 28.27 | 50.69 |
| price to sales ratio | 49.0 | 40.56 | 20.80 |
| pocfratio | 53.84 | 66.61 | -19.17 |
| pfcf ratio | 53.84 | 66.61 | -19.17 |
| pb ratio | 1.43 | 1.2 | 19.15 |
| ptb ratio | 1.43 | 1.2 | 19.15 |
| ev to sales | 66.25 | 58.29 | 13.66 |
| enterprise value over ebitda | 76.1 | 70.77 | 7.53 |
| ev to operating cash flow | 72.79 | 95.72 | -23.95 |
| ev to free cash flow | 72.79 | 95.72 | -23.95 |
| earnings yield | 0.01 | 0.01 | -33.64 |
| free cash flow yield | 0.02 | 0.02 | 23.72 |
| debt to equity | 0.51 | 0.53 | -4.39 |
| debt to assets | 0.33 | 0.34 | -4.15 |
| net debt to ebitda | 19.82 | 21.52 | -7.93 |
| current ratio | 0.74 | 0.9 | -17.94 |
| interest coverage | 2.57 | 2.83 | -9.15 |
| income quality | 3.17 | 1.7 | 86.44 |
| dividend yield | 0.01 | 0.01 | -17.84 |
| payout ratio | 1.74 | 1.41 | 23.80 |
| sales general and administrative to revenue | 0.06 | 0.06 | -7.18 |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.1 | 0.1 | -2.26 |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0.02 | 0.02 | -1.42 |
| graham number | 22.9 | 25.12 | -8.84 |
| roic | 0.09 | 0.01 | 880.58 |
| return on tangible assets | 0.01 | 0.01 | -20.94 |
| graham net net | -27.92 | -27.29 | -2.29 |
| working capital | -43730000 | -12814000 | -241.27 |
| tangible asset value | 4456765000 | 4325087000 | 3.04 |
| net current asset value | -2764520000 | -2718653000 | -1.69 |
| invested capital | 794135000 | 7838106000 | -89.87 |
| average receivables | 96529000 | 93077000 | 3.71 |
| average payables | 124127000 | 109221500 | 13.65 |
| average inventory | -3429999.5 | -3429999 | -0.00 |
| days sales outstanding | 57.27 | 55.95 | 2.36 |
| days payables outstanding | 183.15 | 140.21 | 30.62 |
| days of inventory on hand | 0 | -9.07 | 100.00 |
| receivables turnover | 1.57 | 1.61 | -2.30 |
| payables turnover | 0.49 | 0.64 | -23.44 |
| inventory turnover | 0 | -9.92 | 100.00 |
| roe | 0.01 | 0.01 | -20.93 |
| capex per share | 0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to 0.01 on 2024-09-30 Q3 from 0.01 on 2024-06-30 Q2, representing a change of -20.93%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 0.74 on 2024-09-30 Q3 from 0.90 on 2024-06-30 Q2, representing a change of -17.94%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 42.60 on 2024-09-30 Q3 from 28.27 on 2024-06-30 Q2, representing a change of 50.69%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.51 on 2024-09-30 Q3 from 0.53 on 2024-06-30 Q2, representing a change of -4.39%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-17 09:02:58
I'm still buying Agree Realty's commons despite the REIT selloff, driven by the significant rise in long-term Treasury yields. ADC's strong financials include 12.8% revenue growth, 99.6% leased properties, and an investment-grade tenant base, supporting a 4.3% dividend yield. ADC's prudent debt maturity profile and $2 billion liquidity ensure stability, with no significant refinancing needed while Fed rates remain high.
Sentiment: Positive
Publish Date: 2025-01-15 19:00:00
SAN FRANCISCO and SUZHOU, China , Jan. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343, a potentially best-in-class TOPO1i anti-CLDN18.2 ADC, as monotherapy for the treatment of CLDN18.2-positive advanced pancreatic ductal adenocarcinoma (PDAC) patients who have progressed after at least one line of prior systematic treatment. The BTD for IBI343 was granted based on data from an ongoing Phase 1 study conducted in China, Australia and the U.S. (NCT05458219), which demonstrated favorable safety and tolerability, as well as promising antitumor activity of IBI343 monotherapy in advanced PDAC patients.
Sentiment: Positive
Publish Date: 2025-01-14 16:05:00
ROYAL OAK, Mich. , Jan. 14, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.253 per common share.
Sentiment: Positive
Publish Date: 2025-01-14 14:17:56
Joey Agree, president and CEO at Agree Realty, joins CNBC's The Exchange to discuss the rise in risks for commercial properties, recent retail trends, and more.
Sentiment: Positive
Publish Date: 2025-01-14 13:09:39
Dividend investing has been very rewarding for me. However, I have learned a lot of lessons the hard way. I share some of the most important lessons I have learned in this article.
Sentiment: Positive
Publish Date: 2025-01-14 07:45:00
Despite high-interest rates, REITs like Agree Realty and Realty Income offer attractive valuations and strong fundamentals, making them ideal for passive income investors. ADC boasts a 12% CAGR since 1994, a conservative payout ratio, and a solid balance sheet, offering a 4.27% yield and significant upside potential. Realty Income, with an A-rating and international exposure, yields nearly 6%, has strong liquidity, and continues to diversify, showcasing resilience and growth potential.
Sentiment: Negative
Publish Date: 2025-01-13 07:30:00
-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer -- -- Expect to report initial data from combination cohort in 4Q 2025 or 1Q 2026 -- -- On-track to report additional monotherapy data from dose escalation and expansion cohorts of ongoing Phase 1 clinical trial in 1H 2025 -- -- Plan to present preclinical data for HER3 ADC EO-1022 in 1H 2025 and file an Investigational New Drug (IND) application in 2026 -- BOSTON , Jan. 13, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced program updates and upcoming milestones. "We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
Sentiment: Positive
Publish Date: 2025-01-12 20:04:00
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus' leading Biclonics® technology platform, and Biohaven's next-generation ADC conjugation and payload platform technologies.
Sentiment: Negative
Publish Date: 2025-01-12 09:00:00
US equity markets tumbled this week while benchmark interest rates surged to the cusp of multi-decade highs after a critical slate of employment data showed surprisingly buoyant labor market trends. Prompting a hawkish re-think of Fed policy expectations, inflation worries were further inflamed by surging energy prices amid frigid temperatures across the Central and East, while L.A. battled destructive wildfires. Real estate equities - the most rate-sensitive sector - were significant laggards this week as rate cut expectations soured, with REITs extending their year-end slide into early 2025.
Sentiment: Positive
Publish Date: 2025-01-11 08:05:00
Interest rate peaks often cause short-term S&P 500 selloffs, especially for REITs. I retain hope that REITs may decouple from 10-year Treasury yields once rates stabilize. Baby Boomers' economic impact is profound, influencing inflation, wages, and consumption patterns, with Millennials having a smaller effect at later ages in life. Debating whether dividend growth investors should buy Magnificent 7 stocks, I find GOOGL compelling for its reasonable valuation and growth potential.
Sentiment: Positive
Publish Date: 2025-01-11 07:30:00
Reliable monthly dividends are a game-changer for income investors, providing steady cash flow and financial peace of mind in any market. I share three top-notch monthly dividend payers that offer consistency, growth potential, and the reliability every income-focused portfolio needs. These stocks exemplify stability, rewarding shareholders with dependable payouts you can count on for years, no matter your financial goals.
Sentiment: Positive
Publish Date: 2025-01-07 16:05:00
ROYAL OAK, Mich. , Jan. 7, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that it will release its fourth quarter and full year 2024 operating results after the market closes on Tuesday, February 11, 2025.
Sentiment: Positive
Publish Date: 2025-01-06 16:05:00
2025 Investment Guidance of $1.1 Billion to $1.3 Billion Balance Sheet Pre-Equitized with Liquidity of Over $2.0 Billion ROYAL OAK, Mich. , Jan. 6, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced a summary of its investment activity in 2024, introduced investment guidance for 2025, and provided an update on its portfolio as well as its fourth quarter capital markets activity.
Sentiment: Positive
Publish Date: 2025-01-04 07:00:00
A few months ago, Agree Realty upped its monthly dividend per share. The REIT delivered in the third quarter and looks positioned to keep generating solid AFFO per share growth. Agree Realty's credit rating was recently upgraded to BBB+ on a stable outlook by S&P.
Sentiment: Positive
Publish Date: 2025-01-02 16:05:00
LAUSANNE, Switzerland , Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 20,000 of the Company's common shares to two new employees on January 2, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.
Sentiment: Positive
Publish Date: 2025-01-01 20:29:45
Traditional dividend valuation methods may not apply to all asset classes. Business Development Companies like Blue Owl Capital offer high yields through diverse debt investments, benefiting from higher interest rates and defensive portfolio structures. REITs, despite current underperformance, present opportunities for high yields and potential capital appreciation, especially with future interest rate cuts.
Sentiment: Positive
Publish Date: 2024-12-30 16:30:00
LAUSANNE, Switzerland , Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in LOTIS-5, the Phase 3 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA previously received accelerated approval for the treatment of r/r DLBCL after two or more lines of systemic therapy from the FDA in 2021.
Sentiment: Positive
Publish Date: 2024-12-30 08:25:00
REITs are offering a once-in-a-decade opportunity. They are heavily discounted and some enjoy strong catalysts in 2025. This could lead to significant upside. Here are some of my top picks.
Sentiment: Positive
Publish Date: 2024-12-29 06:00:00
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC) DLL3 highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), respectively 85% and 20-40% Rational combination opportunities with IDEAYA's DNA Damage Repair (DDR) clinical pipeline, including Phase 1 PARG inhibitor IDE161 Targeting US IND filing for SHR-4849 in H1 2025 SOUTH SAN FRANCISCO, Calif. and SHANGHAI , Dec. 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program with Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Sentiment: Positive
Publish Date: 2024-12-28 08:25:00
The REIT market has something for everyone. There are income, growth, and deep value opportunities. But a few REITs have it all. We highlight 2 such REITs to own in 2025.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
